Nausea and vomiting are the commonest side effects related to cancer cytotoxic chemotherapy and radiation therapy, which impact on patients' quality of life and optimal therapy. [1] [2] [3] [4] Therefore, prevention of nausea and vomiting is very important to improve patient compliance and therapeutic effect. Marked benefit in antiemetic therapy has been observed since the introduction of the 5-HT3 receptor antagonists such as granisetron hydrochloride.
3) Due to its well tolerate and high pharmacological activity, granisetron hydrochloride regarded as the first-line antiemetic drugs in clinical, has been used widely in antiemetic therapy. 4) In clinical, it is mainly available for injection and oral dosage forms as tablets or oral solution. For oral route, it produces severe first-pass effect and leads to some difficulties for cancer patients who are unable or unwilling to take an oral dosage forms. On the other hand, intravenous dosage form results in injure and ache for patients. 5) However, significant advantages of transdermal delivery of granisetron hydrochloride in solving these problems could be achieved.
At present, tansdermal dosage forms include patch, 6, 7) microemulsion, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] gels, [19] [20] [21] cataplasm 5) and Aerosol. 22, 23) Microemulsion consisted of oil and aqueous phase, surfactant and cosurfactant, has unique advantages such as good thermodynamic stability, ease of manufacturing and enhancement of the skin permeation of many drugs. [9] [10] [11] [12] [13] [14] [15] Recently, microemulsion has been developed as a potential vehicle for tansdermal delivery of drugs. 24) The aim of this study was to prepare an oil/water (o/w) nanoemulsion system for transdermal delivery of granisetron hydrochloride and evaluate its tansdermal behavior through rat skin to find out the optimum formulation with the highest skin permeability.
ceptor compartment capacity using excised rat skins at 37Ϯ0.5°C. The receptor compartment was filled with 0.9% saline, which was magnetically stirred at 400 rpm throughout the experiment. After the granisetron hydrochloride nanoemulsion samples (0.2 g) were mounted on the epidermal surface of the excised rat skin, at regular time interval, the receiver solution was completely withdrawn and filtered with a 0.22 mm membrane filter to determinate concentration of granisetron hydrochloride by HPLC analytical method as described below. At the same time, fresh 0.9% saline (6.5 ml, 37Ϯ0.5°C) was dispensed into the receptor compartment to maintain sink conditions after each sample was collected.
Drug Quantification The concentration of granisetron hydrochloride in the receptor medium was assayed with a modified reverse phase HPLC method reported previously. 25) Phenomenex LUNA C18 column (150 mmϫ4.6 mm, 5 mm particle sizes) (Phenomenex, U.S.A.) with a guard column (Phenomenex C18, 4.0 mmϫ3.0 mm) was selected and used. The mobile phase was composed of methanol/0.02 M phosphate buffer (pH 4.0) (40 : 60, v/v), running at a flow rate of 1 ml/min with ultraviolet (UV) detection at 303 nm.
The Stability of Nanoemulsion The acceleration stability test and longterm stability test were carried out according to the Technical Standard of Drug Stability Test (Chinese Pharmacopoeia 2005, appendix XIX C). Granisetron hydrochloride nanoemulsion samples prepared by the optimum formulation were stored at 40Ϯ2°C, RH 60Ϯ10% for 6 months in the case of the accelerate stability test, and sampled at months 1, 2, 3 and 6. In the long-term stability test, Granisetron hydrochloride nanoemulsion samples were preserved at 25Ϯ2°C for 12 months, and sampled at months 0, 3, 6, 9 and 12. The appearance, content and related substances as markers of stability were determined according to the methods described above.
Data Analysis In vitro skin permeation study, the cumulative amount of the drug permeation per unit of rat skin surface area (Qt) was determined by the following equation:
Where Ct is the drug concentration of the receiver solution at each sampling time, Ci is the drug concentration of the ith sample, and Vr and Vs represent the volumes of the receiver solution and the sample solution, respectively, A is the effective diffusion area of skin surface. The curve of Qt versus time was analyzed by linear regression to obtain linear regression equation: QtϭktϮb, where k is the slop of the curve. The skin permeation rate at steady-state (Js, mg/cm 2 /h) is calculated by the equation: Jsϭk. Lag time (t) is defined as the first time of detected drug and calculated by the equation: tϭϮb/k (Qtϭ0). Statistical analysis was performed by the Student's t-test and a significance level of less than 0.05 was considered statistically significant.
Results and Discussion
Phase Diagram Study and Nanoemulsion Formation When we investigate pharmaceutical formulation, important criteria of components selection are that these components can be pharmaceutically acceptable. Based on the preliminary experimental results, IPM was chosen as oil phase and the maximum area of o/w nanoemulsion was observed, which was consistent with previous results. 24) Since a great number of surfactants may cause skin irritation, a major determining factor in choosing a surfactant is safety firstly. Non-ionic surfactants are less toxic than ionic surfactants. In general, the formation of o/w nanoemulsion requires the hydrophilic lipophilic balance (HLB) value (Ն10). It was well known that the HLB value of IPM (11.1) was similar to that of Tween 85 (11.0). Kloet et al. reported that the emulsifying effect was the best when the HLB value of selected surfactant was equal to that of oil phase. 26) So, Tween 85 was selected as surfactant. In this study, an ethanol was chosen as cosurfactant, which was necessary to maintain stable o/w nanoemulsion.
The pseudo-ternary phase diagram of IPM as an oil phase, tween 85 as surfactant, ethanol as cosurfactant, water as aqueous phase was developed to ascertain the components concentration range for the formation of nanoemulsion. It was found that o/w nanoemulsion created with the three systems (Figs. 1a-c) was thermodynamically stable, optically The maximum area of o/w nanoemulsion region was observed when K m was 1 : 1, while a very narrow area of o/w nanoemulsion region was obtained at K m 3 : 1. This reason was that ethanol was a polar solvent with the tendency to highly incorporate into aqueous phase and was capable of solubilizing high water content.
27) Therefore, the relatively lower ethanol concentration decreased the hydrophilicity of the mix-surfactant resulted in small area of o/w nanoemulsion region. In contrast, at K m 1 : 3, the low concentration of surfactant reduced the amount of micelle, resulted in low solubilization capacity of nanoemulsion, which a small area of nanoemulsion region was observed.
Effect of the Content of Oil Phase on Skin Permeation
In the present study, on the basis of nanoemulsion regions in the pseudo-ternary phase diagram, when the content of K m (1 : 1) and granisetron hydrochloride was fixed at 40% and 2.5%, respectively, appropriate content of oil was selected and used to prepare granisetron hydrochloride nanoemulsion. The effect of the content of IPM on nanoemulsion characterization and skin permeation was investigated. These results were shown in Table 1 and Fig. 2 , respectively, which showed the effect of the content of IPM ranged from 4.0 to 12.0% on the skin permeation behavior of granisetron hydrochloride. From the Fig. 2 and Table 1 , the cumulative permeation amount of granisetron hydrochloride at 12 h were the highest when 4% of IPM was used and the skin permeation rate increased 3.3-fold in comparison with control group (20% of tween 85 and 20% of ethanol micelle solution containing 2.5% of granisetron hydrochloride without IPM), which demonstrated that nanoemulsion as a transdermal permeation carrier had excellent penetrable ability through skin. In vitro skin permeation study, the skin permeation rate and cumulative amount of granisetron hydrochloride increased with the decreasing IPM content; in contrast, lag time was reduced. Among the formulations containing different IPM content, a significant difference in lag time, cumulative amount and the skin permeation rate was observed (pϽ0.025). One reason was that water in the nanoemulsion system could hydrate skin to promote drug channels wide, which was consistent with the previous results reported. 16, 28) Other was that the drug in nanoemulsion system could penetrate skin in the form of nanoemulsion droplet. From Table 1 , the mean particle size of nanoemulsion increased with the increasing concentration of IPM, which could be attributed to the increase of oil drop of nanoemulsion by further titration of the oil. The result was accordance with previous study with nanoemulsion system where the mean particle sizes of nanoemulsion containing 5% and 15% IPM were 37.0 and 61.9 nm, respectively.
16)

Effect of the Content of NMP on Skin Permeation
Permeation enhancers are commonly used in the formulation of a transdermal drug delivery system for achieving the desired drug penetration rate. NMP is well known to be safe and it has been used to increase the skin permeation of a large number of drugs. In this study, when the IPM content was chosen as 4%, and the content of K m (1 : 1) and granisetron hydrochloride was fixed at 40% and 2.5%, respectively, the effect of different content of NMP in the nanoemulsion system on the skin permeation of granisetron hydrochloride was studied and these results were shown in Table 2 and Fig. 3 . It was found that the cumulative permeation amount ranged from 795.0Ϯ3.89 to 891.8Ϯ2.86 mg/ cm 2 , Js ranged from 71.14Ϯ3.54 to 85.39Ϯ2.90 mg/cm 2 /h and lag time ranged from 0.11Ϯ0.02 to 0.25Ϯ0.01 h demonstrated that the permeation parameters of granisetron hydrochloride nanoemulsion were markedly affected by the content of NMP in the nanoemulsion system. For granisetron nanoemulsion containing NMP, there was a significant difference in lag time, cumulative amount and the skin permeation rate in comparison with the control group (nanoemulsion without NMP) (pϽ0.025), while no markedly change in the skin permeation parameters between nanoemulsion contain- These results were consistent with previous study reported that, 24, 29, 30) the permeation effect of nanoemulsion containing hydrophobic or hydrophilic drugs was markedly enhanced in the existence of NMP in the nanoemulsion system, in comparison with control group (without NMP). In other words, these results indicated that NMP was a more effective transdermal enhancer. As a partition enhancer in the nanoemulsion system, NMP could increase the concentration of granisetron hydrochloride in the aqueous phase, making it improve the permeability of skin. 24) In addition, data from Fig. 3 indicates that granisetron hydrochloride nanoemulsion penetrates rat skin in vitro by passive diffusion. Therefore, the skin permeation rate (Js) decreased with the decrease of drug concentration in the donor compartment at the latter half (6-12 h) . If the drug in nanoemulsion system penetrates skin in the form of nanoemulsion droplet, the mechanisms of enhancement effect of NMP on excise rat skin penetration mainly include ① increasing the thermodynamic activity in the vehicle, ② fluidization of the lipid in the stratum corneum, reducing the diffusional resistance; ③ increasing drug solubility in the skin. 31) Therefore, according to cumulative amount, the skin permeation rate and lag time as marker, we found out the optimum formulation composed of 2.5% granisetron hydrochloride, 4% IPM, 40% tween 85/ethanol (1 : 1) and 10% NMP.
The Stability of Nanoemulsion It was known that characterization of pharmaceutical formulation stability was a 1018
Vol. 58, No. 8 Fig. 3 . In Vitro Permeation-Time Curve through the Rat Skin from Granisetron Hydrochloride Nanoemulsion Containing Different Content of NMP key step in the design of safe, stable and effective drugs. Thus, both the acceleration stability test and long-term stability test were carried out to study on the stability of granisetron hydrochloride nanoemulsion (Tables 3, 4) . The results of the accelerating stability test and long-term stability test showed no marked change in the appearance, content and related substances as indexes (nϭ3; pϾ0.05). Therefore, the granisetron hydrochloride nanoemulsion was stable for at least 12 months at room temperature.
Conclusion
In the present study, an o/w nanoemulsion system for transdermal delivery of granisetron hydrochloride using NMP as transdermal enhancer was developed successfully and the effect of the content of IPM and NMP on the skin permeation behavior of granisetron hydrochloride was evaluated to find out the desirable nanoemulsion formulation with the highest skin permeability. Although the pharmacokinetics has not been studied in animal and clinical experiment, from the results in vitro, we believe that it is promising to reach pharmacologically effective concentration of granisetron with use of new topical formulation. Therefore, further studies are needed to confirm this possibility.
